Fibrocell Science Inc (NASDAQ:FCSC) saw an uptick in trading volume on Monday . 31,266,320 shares changed hands during mid-day trading, an increase of 3,847% from the previous session’s volume of 792,110 shares.The stock last traded at $2.54 and had previously closed at $1.78.

Several brokerages have recently issued reports on FCSC. Zacks Investment Research cut Fibrocell Science from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. ValuEngine cut Fibrocell Science from a “hold” rating to a “sell” rating in a research note on Monday, December 17th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Fibrocell Science in a research note on Thursday, March 28th.

The company has a market capitalization of $18.64 million, a PE ratio of -1.75 and a beta of 1.59.

Fibrocell Science (NASDAQ:FCSC) last announced its quarterly earnings results on Wednesday, March 27th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.48. As a group, research analysts anticipate that Fibrocell Science Inc will post -1.38 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Fibrocell Science stock. Virtu Financial LLC purchased a new stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 48,914 shares of the company’s stock, valued at approximately $120,000. Virtu Financial LLC owned approximately 0.53% of Fibrocell Science at the end of the most recent quarter. 27.75% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Fibrocell Science (FCSC) Sees Unusually-High Trading Volume” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at

Fibrocell Science Company Profile (NASDAQ:FCSC)

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Recommended Story: Straddles

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.